Weill Cornell Medicine

Search Results

Showing results 9951 - 9960 for weill cornell library

Detection of PKD1 and PKD2 Somatic Variants in Autosomal Dominant Polycystic Kidney Cyst Epithelial Cells by Whole-Genome Sequencing. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/detection-pkd1-and-pkd2-somatic-variants-autosomal-dominant-polycystic-kidney

Performance Evaluation of the MatMaCorp COVID-19 2SF Assay for the Detection of SARS-CoV-2 from Nasopharyngeal Swabs. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/performance-evaluation-matmacorp-covid-19-2sf-assay-detection-sars-cov-2

Clinical Performance of SARS-CoV-2 Molecular Tests. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/clinical-performance-sars-cov-2-molecular-tests

Rapid Implementation of Severe Acute Respiratory Syndrome Coronavirus 2 Emergency Use Authorization RT-PCR Testing and Experience at an Academic Medical Institution. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/rapid-implementation-severe-acute-respiratory-syndrome-coronavirus-2-emergency

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/safety-tolerability-and-clinical-outcomes-hydroxychloroquine-hospitalized

PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/prmt5-inhibition-drives-therapeutic-vulnerability-combination-treatment-bcl-2

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/cellular-proliferation-multiplex-immunohistochemistry-identifies-high-risk

A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/phase-i-trial-palbociclib-plus-bortezomib-previously-treated-mantle-cell

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/mutually-exclusive-cyclin-dependent-kinase-4cyclin-d1-and-cyclin-dependent

Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. | Pathology & Laboratory Medicine

...Weill Cornell Medicine © Weill Cornell Medicine....

https://pathology.weill.cornell.edu/research/publications/homeostatic-cell-cycle-control-blys-induction-cell-cycle-entry-not-g1s

Showing results 9951 - 9960 for weill cornell library